The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers c
Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen.
OPEN Health’s Christine Drewienkiewicz, Sara Black and Annie Rankin on advances in modern oncology and how pharma can help ensure maximum patient benefit
